Brainstorm Cell Therapeutics IncNASDAQ:BCLINASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE1.2500
- TODAY'S CHANGE (%)0.0100 (0.8065%)
- Bid / Lots1.2200/ 8
- Ask / Lots1.2700/ 3
- Open / Previous Close1.2200 / 1.2400
- Day Range
- 52 Week Range
- Volume44,281
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BCLI |
|---|---|---|
| 09:32 ET | 177 | 1.22 |
| 09:39 ET | 100 | 1.2535 |
| 09:42 ET | 100 | 1.23 |
| 09:50 ET | 1311 | 1.23 |
| 09:55 ET | 100 | 1.21 |
| 10:02 ET | 2684 | 1.2373 |
| 10:15 ET | 1572 | 1.23 |
| 10:22 ET | 2600 | 1.2301 |
| 10:27 ET | 2600 | 1.23 |
| 10:31 ET | 100 | 1.23 |
| 10:36 ET | 886 | 1.21 |
| 10:49 ET | 100 | 1.23 |
| 10:54 ET | 886 | 1.2247 |
| 11:00 ET | 100 | 1.21 |
| 11:18 ET | 100 | 1.22 |
| 11:32 ET | 100 | 1.23 |
| 12:03 ET | 100 | 1.22 |
| 12:14 ET | 100 | 1.22 |
| 12:15 ET | 100 | 1.21 |
| 12:51 ET | 100 | 1.21 |
| 01:09 ET | 1883 | 1.23 |
| 01:13 ET | 4982 | 1.25 |
| 01:15 ET | 3273 | 1.25 |
| 01:27 ET | 231 | 1.221 |
| 01:40 ET | 100 | 1.2211 |
| 02:07 ET | 100 | 1.24 |
| 02:25 ET | 200 | 1.24 |
| 02:27 ET | 290 | 1.25 |
| 02:41 ET | 300 | 1.24 |
| 02:43 ET | 1979 | 1.25 |
| 02:50 ET | 200 | 1.23 |
| 02:56 ET | 1200 | 1.245 |
| 03:14 ET | 200 | 1.23 |
| 03:19 ET | 200 | 1.23 |
| 03:32 ET | 264 | 1.2201 |
| 03:37 ET | 600 | 1.23 |
| 03:39 ET | 500 | 1.23 |
| 03:42 ET | 1197 | 1.24 |
| 03:44 ET | 400 | 1.245 |
| 03:48 ET | 125 | 1.24 |
| 03:51 ET | 300 | 1.2498 |
| 03:57 ET | 763 | 1.245 |
| 04:00 ET | 5094 | 1.25 |
Nov 14, 2024
BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update, from 4:30PM ET on Thursday Nov 14, 2024 by Dow Jones
4:30PM ET on Thursday Nov 14, 2024 by Dow JonesPress Release: BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update, from 4:30PM ET on Thursday Nov 14, 2024 by Dow Jones
4:30PM ET on Thursday Nov 14, 2024 by Dow Jones
Nov 11, 2024
BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn(R) Phase 3b Trial Manufacturing, from 6:00AM ET on Monday Nov 11, 2024 by Dow Jones
6:00AM ET on Monday Nov 11, 2024 by Dow Jones
Oct 30, 2024
BrainStorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement, from 6:00AM ET on Wednesday Oct 30, 2024 by Dow Jones
6:00AM ET on Wednesday Oct 30, 2024 by Dow Jones
Oct 28, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Brainstorm Cell Therapeutics Inc | 6.6M | -0.4x | --- |
Transcode Therapeutics Inc | 6.6M | 0.0x | --- |
Virpax Pharmaceuticals Inc | 6.6M | -0.1x | --- |
NLS Pharmaceutics AG | 6.8M | -0.5x | --- |
National Graphite Corp | 6.8M | -2.0x | --- |
Adial Pharmaceuticals Inc | 6.5M | -0.2x | --- |
Company Information
BrainStorm Cell Therapeutics Inc. is a developer of autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The neurodegenerative diseases include Amyotrophic Lateral Sclerosis (ALS), Progressive Multiple Sclerosis (PMS), Alzheimer’s disease (AD), and others. The Company is engaged in the clinical development and commercialization of the NurOwn technology platform used to produce autologous mesenchymal stem cells- neurotrophic factors (MSC-NTF) cells. NurOwn leverages cell culture methods to induce autologous bone marrow derived MSCs to secrete high levels of NTFs, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. Autologous MSC-NTF cells is for the treatment of ALS. It has completed a phase III trial in ALS. Its wholly owned subsidiary, BrainStorm Cell Therapeutics Ltd., holds exclusive rights to commercialize NurOwn technology.
Contact Information
- Headquarters
- 1325 Avenue Of Americas, 28Th FloorNEW YORK, NY, United States 10019
- Phone
- 201-488-0460
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Jacob Frenkel
- President, Chief Executive Officer
- Chaim Lebovits
- Independent Vice Chairman of the Board
- Irit Arbel
- Interim Chief Financial Officer, Controller
- Alla Patlis
- Chief Operating Officer, Executive Vice President
- Hartoun Hartounian
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $6.6M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 5.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.31 |
EPS | $-3.46 |
Book Value | $-1.20 |
P/E Ratio | -0.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
